Share-based Payment Arrangement, Expense of PUMA BIOTECHNOLOGY, INC. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PUMA BIOTECHNOLOGY, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • PUMA BIOTECHNOLOGY, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,673,000, a 19% decline year-over-year.
  • PUMA BIOTECHNOLOGY, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $7,079,000, a 21% decline year-over-year.
  • PUMA BIOTECHNOLOGY, INC. annual Share-based Payment Arrangement, Expense for 2024 was $8,245,000, a 20% decline from 2023.
  • PUMA BIOTECHNOLOGY, INC. annual Share-based Payment Arrangement, Expense for 2023 was $10,247,000, a 13% decline from 2022.
  • PUMA BIOTECHNOLOGY, INC. annual Share-based Payment Arrangement, Expense for 2022 was $11,826,000, a 64% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PUMA BIOTECHNOLOGY, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,079,000 $1,673,000 -$381,000 -19% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $7,460,000 $1,628,000 -$434,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,894,000 $2,026,000 -$351,000 -15% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $8,245,000 $1,752,000 -$680,000 -28% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $8,925,000 $2,054,000 -$491,000 -19% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $9,416,000 $2,062,000 -$370,000 -15% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $9,786,000 $2,377,000 -$461,000 -16% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $10,247,000 $2,432,000 -$196,000 -7.5% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $10,443,000 $2,545,000 -$285,000 -10% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,728,000 $2,432,000 -$788,000 -24% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $11,516,000 $2,838,000 -$310,000 -9.8% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $11,826,000 $2,628,000 -$1,624,000 -38% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $13,450,000 $2,830,000 -$1,452,000 -34% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $14,902,000 $3,220,000 -$15,019,000 -82% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $29,921,000 $3,148,000 -$2,712,000 -46% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2022 Q1
Q4 2021 $32,633,000 $4,252,000 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $4,282,000 -$3,283,000 -43% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $18,239,000 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $5,860,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 $7,565,000 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q3 2016 $109,671,000 $29,751,000 +$4,795,000 +19% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2016 2016 Q3
Q2 2016 $104,876,000 $28,729,000 +$535,000 +1.9% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2016 2016 Q2
Q1 2016 $104,341,000 $29,510,000 +$9,407,000 +47% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 $94,934,000 $21,681,000 01 Oct 2015 31 Dec 2015 10-K 29 Feb 2016 2015 FY
Q3 2015 $24,956,000 +$14,507,000 +139% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $28,194,000 +$21,027,000 +293% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $20,103,000 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q3 2014 $10,449,000 +$8,643,000 +479% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $7,167,000 +$5,722,000 +396% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q4 2013 $7,519,000 $3,093,000 -$22,516,000 -88% 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $30,035,000 $1,806,000 +$8,032,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2013 2013 Q3
Q2 2013 $22,003,000 $1,445,000 +$1,247,000 +630% 01 Apr 2013 30 Jun 2013 10-Q 06 Aug 2013 2013 Q2
Q1 2013 $20,756,000 $1,175,000 +$1,126,000 +2298% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2013 2013 Q1
Q4 2012 $19,630,000 $25,609,000 01 Oct 2012 31 Dec 2012 10-K 03 Mar 2014 2013 FY
Q3 2012 $6,226,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $198,000 01 Apr 2012 30 Jun 2012 10-Q 06 Aug 2013 2013 Q2
Q1 2012 $49,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1

PUMA BIOTECHNOLOGY, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,245,000 -$2,002,000 -20% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $10,247,000 -$1,579,000 -13% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $11,826,000 -$20,807,000 -64% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $32,633,000 -$3,942,000 -11% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $36,575,000 -$20,752,000 -36% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $57,327,000 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2022 2021 FY
2015 $94,934,000 +$55,783,000 +142% 01 Jan 2015 31 Dec 2015 10-K 29 Feb 2016 2015 FY
2014 $39,151,000 +$31,632,000 +421% 01 Jan 2014 31 Dec 2014 10-K 29 Feb 2016 2015 FY
2013 $7,519,000 -$12,111,000 -62% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $19,630,000 +$11,977,000 +157% 01 Jan 2012 31 Dec 2012 10-K 03 Mar 2014 2013 FY
2011 $7,653,000 01 Jan 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.